Monitoring the Session

SB 2625

Campbell’s bill on providing abortion-inducing drugs

Died in committee

Verdict: No flags

No flagsInitial review
Sen. Donna CampbellRSenate 25

Initial review · graded Oct 19, 2026 · Headline, summary and grade are analysis of the bill text, not a finding about any person · How we grade

Caption

relating to the provision of an abortion-inducing drug.

Caption from analyzed text · version I.

Summary

A physician physically in Texas, with an in-person exam.

The bill tightens Texas rules on who may hand out abortion-inducing drugs, requiring that the provider be a physician who is physically in Texas and examines the pregnant woman in person when the drug is given. It also requires the physician to schedule an in-person follow-up visit within 14 days to confirm the pregnancy has ended and check for continued bleeding. Out-of-state doctors who now fall under consultation exemptions from Texas licensing rules would lose those exemptions for any consultation tied to abortion-inducing drugs.

Labels

Labels: NEVER GOT A HEARING. Filed Mar 13, 2025 and referred to the Senate State Affairs committee. No public hearing. The bill died.

Receipt

The receipt

89R-SB2625 · 2025-03-13

SOLD BY

ITEM

relating to the provision of an abortion-inducing drug.

WHAT IT DOES

A physician physically in Texas, with an in-person exam.

The bill tightens Texas rules on who may hand out abortion-inducing drugs, requiring that the provider be a physician who is physically in Texas and examines the pregnant woman in person when the drug is given. It also requires the physician to schedule an in-person follow-up visit within 14 days to confirm the pregnancy has ended and check for continued bleeding. Out-of-state doctors who now fall under consultation exemptions from Texas licensing rules would lose those exemptions for any consultation tied to abortion-inducing drugs.

CHARGES

[ ] NONE FOUND

TOTAL

No fiscal note in the loaded record.

HISTORY

  1. Received by the Secretary of the Senate
  2. Filed
  3. Read first time
  4. Referred to State Affairs
FILED UNDER

Beats not yet reviewed.

No flags

THANK YOU FOR CHECKING THE RECEIPT

CAMPAIGN PAID FOR BY

CAMPAIGN PAID FOR BY

Donors

Donors report through Friends of Donna Campbell.

Not tied to this bill.

Sources

The author's campaign account only. Own money and internal transfers are separate on the member page.

Derived itemized flow · Oct 27, 2024 to Jun 30, 2026. State data as of Nov 4, 2026.

Derived itemized contributions on live regular reports and uncovered special-session dates. Internal account transfers and daily reports are excluded.

Money

Missing data does not establish zero giving. Display amounts are rounded.

Votes

No floor vote loaded for this bill.

Fiscal

No fiscal note in the loaded record.

How this was graded

Analysis of text version I by claude-opus-5-5, Oct 19, 2026, against the published rubric.

Sources

Texas Senate · Filed Mar 13, 2025

04/03/2025 S Referred to State Affairs

Texas Legislature Online · Introduced

Data snapshot Oct 26, 2026 at 4:20 AM CDT. Grades, charges, quotes and corrections follow the published record.

Senate committee · State Affairs · Final status: Died in committee

Companion

HB 4593 by Troxclair (similar)

Subjects

Abortion

MEDICINE & PRESCRIPTION DRUGS

PREGNANCY & CHILDBIRTH

Text

The text as introduced · 441 words

By: Campbell, Paxton
S.B. No. 2625

A BILL TO BE ENTITLED

AN ACT

relating to the provision of an abortion-inducing drug.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. Section 171.063, Health and Safety Code, is

amended by amending Subsections (a) to read as follows:

(a) A person may not knowingly provide an abortion-inducing

drug to a pregnant woman for the purpose of inducing an abortion in

the pregnant woman or enabling another person to induce an abortion

in the pregnant woman unless:

(1) the person who provides the

abortion-inducing drug is a physician; [ and ]

(2) the person is physically present in this

state and personally examines the pregnant woman in person at the

time the person provides the abortion-inducing medication to the

pregnant woman; and

(3) the provision of the abortion-inducing drug

satisfies the protocol authorized by this subchapter.

(e) A physician who provides the abortion-inducing drug, or

the physician's agent, must schedule a n in person follow-up visit

for the woman to occur not later than the 14th day after the

earliest date on which the abortion-inducing drug is administered

or used or the abortion is performed or induced. At the follow-up

visit, the physician must:

(1) confirm that the woman's pregnancy is completely

terminated; and

(2) assess any continued blood loss.

SECTION 2. Section 151.056, Occupations Code, is amended by

amending Subsection (b) and adding Subsection (b-1) to read as

follows:

(b) Except as provided by Subsection (b-1), this [ This ]

section does not apply to the act of:

(1) a medical specialist located in another

jurisdiction who provides only episodic consultation services on

request to a physician licensed in this state who practices in the

same medical specialty;

(2) a physician located in another jurisdiction who is

providing consultation services to a medical school as defined by

Section.61.501, Education Code;

(3) a physician located in another jurisdiction who is

providing consultation services to an institution subject to:

(A) Subchapter C, Chapter 73, Education Code; or

(B) Subchapter K, Chapter 74, Education Code; or

(4) a physician located in another jurisdiction of a

state having borders contiguous with the borders of this state who

is the treating physician of a patient and orders home health or

hospice services for a resident of this state to be delivered by a

home and community support services agency licensed in this state.

(b-1) This section applies to any consultation service

described in Subsection (b) if the service relates to the provision

of an abortion-inducing drug, as defined by Section 171.061, Health

and Safety Code.

SECTION 3. This Act takes effect September 1, 2025.